Advaxis reaches important regulatory milestone for axalimogene filolisbac with submission of Conditional MAA to treat metastatic cervical cancer in patients who progress beyond first-line therapy The MAA submission is centered around the encouraging results from the GOG-0265 study Each year, more

Peer-reviewed published article shows treatment with axalimogene filolisbac resulted in an overall 12-month survival rate of approximately 35% "A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes-Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical

Medical Sciences 2018, 6(1), 9

At the European Gynecological Oncology Congress (ESGO) 2017, held in Vienna, a symposium on immunotherapy took place: A New Strategy for the Treatment of Cervical Cancer, sponsored by Advaxis, Inc.  

Dr. Christian Marth, the chair of the symposium, and Dr. Sharad Ghamande, a Gynecological Oncologist coordinating a clinical study of the immunotherapy drug axalimogene filolisbac, shared with us their views about the current state of immunotherapy in cervical cancer.

"Combination TIGIT blockade with Listeria-based immunotherapy enhances antigen-specific antitumor immunity" PRINCETON , N.J.--( BUSINESS WIRE )-- Advaxis, Inc.  (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products,

All patients who completed treatment had complete clinical response "We are delighted to have these promising data highlighted in this prestigious, peer-reviewed journal. The complete clinical response demonstrated in patients who completed the combination treatment is very encouraging,

nternational Journal of Radiation Oncology

ADXS11-0011 Lm-LLO is a live attenuated Listeria monocytogenes (Lm) bacterium bioengineered to secrete the HPV-16 E7 protein fused with a truncated fragment of listeriolysin O (tLLO) that preferentially infects antigen-presenting cells. Exposure to ADXS11-001 may stimulate T-cells to target HPV-transformed cells. The objective of this study was to obtain safety and preliminary efficacy data of the combination of ADXS11-001 with mitomycin, FU and intensity modulated radiation